EMERADE 0.5 MG / 0.5 ML
EPINEPHRINE (EPINEPHRINE BITARTRATE) : 0.5 MG / 0.5 ML · DIN 02458454 · BAUSCH HEALTH, CANADA INC.
Health Canada status: CANCELLED POST MARKET
What is EMERADE?
EMERADE 0.5 MG / 0.5 ML contains EPINEPHRINE (EPINEPHRINE BITARTRATE) : 0.5 MG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02458454, held by BAUSCH HEALTH, CANADA INC., supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 16-Mar-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EMERADE used for?
EMERADE is indicated for the emergency treatment of anaphylactic reactions in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. EMERADE is intended for immediate self-administration for the emergency treatment of severe allergic reactions (Type I), including anaphylaxis associated with foods, stinging and biting insects, medications, latex, idiopathic anaphylaxis, exercise-induced anaphylaxis, and other allergens.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02458454 |
|---|---|
| Brand name | EMERADE |
| Generic / active ingredient | EPINEPHRINE (EPINEPHRINE BITARTRATE) : 0.5 MG / 0.5 ML |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 0.5 MG / 0.5 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Ethical |
| ATC code | C01CA24 EPINEPHRINE |
| AHFS class | 12:12.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 16-Mar-2026 |
| Original market date | 2020-10-08 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
Is EPINEPHRINE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by PFIZER CANADA ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C01CA24 EPINEPHRINE. 7 of 29 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADRENALIN | 1 MG | SOLUTION | SEARCHLIGHT PHARMA INC | MARKETED | DIN 00155357 |
| EPINEPHRINE INJECTION | 1 MG / 10 ML | SOLUTION | LABORATOIRE AGUETTANT | MARKETED | DIN 02521148 |
| EPINEPHRINE INJECTION USP | 1 MG / 1 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02435810 |
| EPINEPHRINE INJECTION USP | 1 MG / 10 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 00710814 |
| EPINEPHRINE INJECTION USP | Strength | Solution | PFIZER CANADA ULC 17300 Trans-Canada Highway Kirkland Quebec Canada H9J 2M5 | MARKETED | DIN 00721891 |
| EPIPEN | 0.3 MG / 0.3 ML | SOLUTION | MYLAN SPECIALTY LP | MARKETED | DIN 00509558 |
| EPIPEN JR | 0.15 MG / 0.3 ML | SOLUTION | MYLAN SPECIALTY LP | MARKETED | DIN 00578657 |
| ADRENACLICK 0.15MG AUTO-INJECTOR | 0.15 MG / 0.15 ML | SOLUTION | AMEDRA PHARMACEUTICALS LLC | CANCELLED PRE MARKET | DIN 02354322 |
| ADRENACLICK 0.30MG AUTO-INJECTOR | 0.30 MG / 0.30 ML | SOLUTION | AMEDRA PHARMACEUTICALS LLC | CANCELLED PRE MARKET | DIN 02354330 |
| ALLERJECT | 0.15 MG / 0.15 ML | SOLUTION | VALEO PHARMA INC | CANCELLED POST MARKET | DIN 02382059 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.